Androgen deprivation therapies (ADTs) are important treatments which inhibit androgen-
induced prostate cancer (PCa) progression by either preventing androgen biosynthesis (eg …

Prostate cancer (PCa) progression relies on androgen receptor (AR) action. Preventing AR's
ligand-activation is the frontline treatment for metastatic PCa. Androgen deprivation therapy …

Androgen receptor (AR) action is a hallmark of prostate cancer (PCa) with androgen
deprivation being standard therapy. Yet, resistance arises and aberrant AR signaling …

The androgen receptor (AR) is a member of the ligand-activated nuclear receptor family of
transcription factors. AR's transactivation activity is turned on by the binding of androgens …

Incorporation of histone variant H3. 3 comprises active territories of chromatin. Exploring the
function of H3. 3 in prostate cancer (PC), we found that knockout (KO) of H3. 3 chaperone …

A major challenge to the treatment of advanced prostate cancer (PCa) is the development of
resistance to androgen-deprivation therapy (ADT) and chemotherapy. It is imperative to …

The androgen receptor (AR) remains a key driver of prostate cancer (PCa) progression,
even in the advanced castrate-resistant stage, where testicular androgens are absent. It is …

Simple Summary For patients whose prostate cancer spreads beyond the confines of the
prostate, treatment options continue to increase. However, we are missing the information …

Prostate cancer (CaP) is the second leading cause of cancer-related deaths in western men.
Because androgens drive CaP by activating the androgen receptor (AR), blocking AR's …

Sustained reliance on androgen receptor (AR) after failure of AR-targeting androgen
deprivation therapy (ADT) prevents effective treatment of castration-recurrent (CR) prostate …